ArticlePloS one2015
Purinergic P2Y12 Receptor Activation in Eosinophils and the Schistosomal Host Response.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- A trial of type 12 purinergic (P2YThe Journal of allergy and clinical immunology · 2019Trial
- Review
- Platelets, inflammation, and purinergic receptors in chronic kidney disease.Kidney international · 2024Review
- Endogenous PGD2 acting on DP2 receptor counter regulates Schistosoma mansoni infection-driven hepatic granulomatous fibrosis.PLoS pathogens · 2024Article
- The Signaling Pathway of the ADP Receptor P2YInternational journal of molecular sciences · 2023Review
- Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function.Research and practice in thrombosis and haemostasis · 2023Article
- Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease.Nature communications · 2022Article
- Review
- Review
- Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.Immunopharmacology and immunotoxicology · 2021Review
- Eosinophils and helminth infection: protective or pathogenic?Seminars in immunopathology · 2021Review
- Review
- P2YInternational journal of molecular sciences · 2020Review
- Eosinophils and Purinergic Signaling in Health and Disease.Frontiers in immunology · 2020Review
- ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12.Cell death & disease · 2019Article
- The synergistic effects of clopidogrel with montelukast may be beneficial for asthma treatment.Journal of cellular and molecular medicine · 2019Article
- Purinergic receptors and neglected tropical diseases: why ignore purinergic signaling in the search for new molecular targets?Journal of bioenergetics and biomembranes · 2018Review
- Antithrombotic Agents and Cancer.Cancers · 2018Review
- P2YFrontiers in pharmacology · 2018Review
- Purinergic signaling in schistosomal infection.Biomedical journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
Identifying new target molecules through which eosinophils secrete their stored proteins may reveal new therapeutic approaches for the control of eosinophilic disorders such as host immune responses to parasites. We have recently reported the expression of the purinergic P2Y12 receptor (P2Y12R) in human eosinophils; however, its functional role in this cell type and its involvement in eosinophilic inflammation remain unknown. Here, we investigated functional roles of P2Y12R in isolated human eosinophils and in a murine model of eosinophilic inflammation induced by Schistosoma mansoni (S. mansoni) infection. We found that adenosine 5'-diphosphate (ADP) induced human eosinophils to secrete eosinophil peroxidase (EPO) in a P2Y12R dependent manner. However, ADP did not interfere with human eosinophil apoptosis or chemotaxis in vitro. In vivo, C57Bl/6 mice were infected with cercariae of the Belo Horizonte strain of S. mansoni. Analyses performed 55 days post infection revealed that P2Y12R blockade reduced the granulomatous hepatic area and the eosinophilic infiltrate, collagen deposition and IL-13/IL-4 production in the liver without affecting the parasite oviposition. As found for humans, murine eosinophils also express the P2Y12R. P2Y12R inhibition increased blood eosinophilia, whereas it decreased the bone marrow eosinophil count. Our results suggest that P2Y12R has an important role in eosinophil EPO secretion and in establishing the inflammatory response in the course of a S. mansoni infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.